Barclays Maintains Equal-Weight on Bausch Health Companies, Raises Price Target to $9
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
Bausch Health And Gastroenterology Unit Salix Pharmaceuticals To Present New Data On Cirrhosis Trends And Severe Alcohol-Associated Hepatitis At The Liver Meeting, November 5–9
Bausch Health Companies Consensus Price Target Increased by 11.58% to $7.29
Up 55% in October: Is Bausch Health’s turnaround just getting started?
Bausch Health Companies Inc. 2026 Q3 - Results - Earnings Call Presentation
Jefferies Maintains Hold on Bausch Health Companies, Raises Price Target to $8
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10
Bausch Health Companies Inc. Q3 2026 Earnings Call Summary
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
Bausch Health Companies Inc. Reports Third Quarter 2026 Consolidated Revenues of $2.94 billion
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Bausch: Q3 Earnings Snapshot
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health Announces US$50 Million Share Repurchase Program
Bausch Health Companies Q3 2026 Earnings Call Transcript
Bausch Health Companies Announces $50M Buyback Plan
Bausch Health Companies Raises FY2026 Sales Guidance from $10.790B-$11.040B to $10.975B-$11.175B vs $10.927B Est
Bausch Health Companies Q3 Adj. EPS $1.77 Beats $1.29 Estimate, Sales $2.941B Beat $2.757B Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.